Pilocarpine as a glaucoma drug provides up to what percentage reduction in intraocular pressure (IOP)?

Pilocarpine, a carbonic anhydrase inhibitor used in the treatment of glaucoma, primarily works by stimulating the muscarinic receptors in the eye. This results in increased aqueous humor outflow, which effectively lowers intraocular pressure (IOP). Clinical studies and practical applications have shown that pilocarpine can achieve a reduction in IOP typically in the range of 20% to 30%, with some patients experiencing even greater reductions depending on individual response and severity of glaucoma.

The correct choice reflects the noted efficacy of pilocarpine, which is often reported to provide a reduction of up to 30% in IOP in many cases. This level of reduction is significant and highlights the role of pilocarpine as a valuable therapeutic option in managing glaucoma, particularly for patients who may not respond adequately to other treatments. In practice, although the variability of response can occur, the 30% reduction aligns well with the expectations set in pharmacological studies and clinical guidelines.